Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101413 · ClinicalTrials.gov registry record · Phase 2
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00101413 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 52 participants.
The verdict
NCT00101413, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate if BAY43-9006 has an effect on the tumors, how long the effect continues, if the patients receiving BAY43-9006 will live longer. * If BAY43-9006 has an effect on the quality of life of patients with non-small cell lung cancer. * If BAY43-9006 helps to slow the worsening of non-small cell lung cancer. * If BAY43-9006 prevents the growth of, or shrinks non-small cell lung tumors and/or their metastases.
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101413
The ClinicalTrials.gov registry entry for NCT00101413 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.
NCT00101413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00101413 about?
NCT00101413 is a clinical study titled "BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)". The purpose of the study is to evaluate if BAY43-9006 has an effect on the tumors, how long the effect continues, if the patients receiving BAY43-9006 will live longer. * If BAY43-9006 has an effect on the quality of life of patients with non-small cell lung cancer. * If BAY43-9006 helps to slow th...
What is the current status of trial NCT00101413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-04. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00101413?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00101413?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.